Claims for Patent: 10,350,093

Summary for Patent: 10,350,093

Title:	Degradable implantable medical devices
Abstract:	Devices and methods are provided for an implantable medical device which is degradable over a clinically relevant period of time. The medical devices may have the form of implants, graft implants, vascular implants, non vascular implants, wound closure implants, sutures, drug delivery implants, biologic delivery implants, urinary tract implants, inter-uterine implants, organ implants, bone implants including bone plates, bone screws, dental implants, spinal disks, or the like. In preferred embodiments, the implantable medical device comprises an implantable luminal prosthesis, such as vascular and non-vascular stents and stents grafts.
Inventor(s):	Yan; John (Los Gatos, CA), Sirhan; Motasim (Los Altos, CA), Cryer; Brett (Sunnyvale, CA), Bhat; Vinayak (Cupertino, CA)
Assignee:	Elixir Medical Corporation (Milpitas, CA)
Application Number:	14/998,288
Patent Claims:	1. A degradable, implantable stent comprising: a tubular body comprising a corrodible metal or metal alloy including at least one corrosion enhancing element within the corrodible metal or metal alloy and at least one corrosion resisting element; and a passivation layer or a coating incorporated in or covering at least a portion of the body; wherein one metal in the corrodible metal alloy comprises at least 90% of the metal alloy; and wherein said stent degrades in about one month to about five years in a physiological environment. 2. A stent of claim 1, wherein the metal alloy is selected from the group consisting of bismuth, cobalt, copper, indium, iridium, iron, magnesium, molybdenum, nickel, niobium, silver, tin, tungsten, zinc, zirconium and combinations thereof. 3. A stent of claim 1 wherein the metal comprises bismuth, carbon, chromium, cobalt, copper, indium, iridium, iron, magnesium, molybdenum, nickel, niobium, silicon, silver, tin, titanium, tungsten, vanadium, zinc, zirconium, or a combination thereof. 4. A stent of claim 1, wherein the corrosion enhancing agent is selected from the group consisting of calcium, carbon, copper, iron, magnesium, sulfide, silicon, silicates, sulfur, and combinations thereof. 5. A stent of claim 1, wherein the corrosion resisting element comprises chromium, nickel or molybdenum. 6. A stent of claim 1, wherein the at least one corrosion enhancing element is greater than approximately 0.01% of the corrodible metal or metal alloy composition by weight. 7. A stent of claim 1, wherein the at least one corrosion resisting element is less than approximately 15% of the corrodible metal or metal alloy composition by weight. 8. A stent as in claim 1, wherein the coating covers at least a portion of the tubular body and the coating comprises a degradable polymer. 9. A stent as in claim 8, wherein the degradable polymer is selected from the group consisting of poly(lactic acids), poly(D-lactic acid), poly(L-lactic acid), poly(DL-lactic acid), copolymers of poly(lactic acids), poly lactates, poly(glycolic acid), poly glycolates, poly dioxanone, poly(ethyl glutamate), poly(hydroxybutyrate), polyhydroxyvalerate, poly (.epsilon.-caprolactone), polyanhydride, poly(ortho esters); poly(ether esters), poly (iminocarbonates), poly alkylene carbonates, polyethylene carbonate, poly trimethylene carbonate, starch based polymers, polyester amides, polyester amines, polycyanoacrylates, polyphosphazenes, poly ethylene glycols, poly ethylene oxide, N-vinyl-2-pyrrolidone, aliphatic polyesters, copolymers of poly(D-lactic acid) and poly(.epsilon.-caprolactone), copolymers of poly(L-lactic acid) and poly(.epsilon.-caprolactone), and copolymers of poly(DL-lactic acid) and poly(.epsilon.-caprolactone). 10. A stent as in claim 1, further comprising at least one therapeutic agent. 11. A stent as in claim 10, wherein at least one of the therapeutic agents is selected from the group consisting of immunomodulators, anti-cancer agents, anti-proliferative agents, anti-inflammatory agents, antithrombotic agents, antiplatelet agents, antifungal agents, antidiabetic agents, antihyperlipidimia agents, antiangiogenic agents, angiogenic agents, antihypertensive agents, contraceptive agents, anti depressant agents, anti seizure agents, pain control agents, anti-addictive agents, healing promoting drugs, fertility agents, metabolism control agents, and combinations thereof. 12. A stent as in claim 10, wherein at least one of the therapeutic agents is selected from the group consisting of acivicin, aclarubicin, acodazole, acronycine, adozelesin, alanosine, aldesleukin, allopurinol sodium, altretamine, aminoglutethimide, amonafide, ampligen, amusacrine, androgens, anguidine, aphidicolin glycinate, asaley, asparaginase, 5-azacitidine, azathioprine, Bacillus calmette-guerin (BCG), Baker's Antifol (soluble), beta-2'-deoxythioguanosine, bisantrene HCl, bleomycin sulfate, busulfan, buthionine sulfoximine, BWA 773U82 (Crisnatol mesylate), BW 502U83.HCl (arylmethylaminopropanediols), ceracemide, carbetimer, carboplatin, carmustine, chlorambucil, chloroquinoxaline-sulfonamide, chlorozotocin, chromomycin A3 (Toyomycin), cisplatin, cladribine, corticosteroids, Corynebacterium parvum, CPT-11 (Camptothecin-11/Irinotecan), crisnatol, cyclocytidine, cyclophosphamide, cytarabine, cytembena, dabis maleate, dacarbazine, dactinomycin, daunorubicin HCl, deazauridine, dexrazoxane, dianhydrogalactitol, diaziquone, dibromodulcitol, didemnin B, diethyldithiocarbamate, diglycoaldehyde, dihydro-5-azacytidine, doxorubicin, echinomycin, edatrexate, edelfosine, eflomithine, buffered intrathecal electrolyte/dextrose injection, elsamitrucin, epirubicin, esorubicin, estramustine phosphate, estrogens, etanidazole, ethiofos, etoposide, fadrazole, fazarabine, fenretinide, filgrastim, finasteride, flavone acetic acid, floxuridine, fludarabine phosphate, 5-fluorouracil, 20% intravascular perflurochemical emulsion, flutamide, gallium nitrate, gemcitabine, goserelin acetate, hepsulfam, hexamethylene bisacetamide, homoharringtonine, hydrazine sulfate, 4-hydroxyandrostenedione, hydroxyurea, idarubicin HCl, ifosfamide, interferon alfa, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6,4-ipomeanol, iproplatin, isotretinoin, leucovorin calcium, leuprolide acetate, levamisole, liposomal daunorubicin, liposome encapsulated doxorubicin, lomustine, lonidamine, maytansine, mechlorethamine hydrochloride, melphalan, menogaril, merbarone, 6-mercaptopurine, mesna, methanol extraction residue of Bacillus calmette-guerin, methotrexate, N-methylformamide, mifepristone, mitoguazone, mitomycin-C, mitotane, mitoxantrone hydrochloride, monocyte/macrophage colony-stimulating factor, nabilone, nafoxidine, neocarzinostatin, octreotide acetate, ormaplatin, oxaliplatin, PALA (N-(phosphonacetyl)-L-aspartic acid), pentostatin, piperazinedione, pipobroman, pirarubicin, piritrexim, piroxantrone hydrochloride, granulocyte macrophage colony stimulating factor/interleukin-3 fusion protein (PIXY-321), plicamycin, porfimer sodium, prednimustine, procarbazine, progestins, pyrazofurin, razoxane, sargramostim, semustine, spirogermanium, spiromustine, streptonigrin, streptozocin, sulofenur, suramin sodium, tamoxifen, taxotere, tegafur, teniposide, terephthalamidine, teroxirone, thioguanine, thiotepa, thymidine, tiazofurin, topotecan, toremifene, tretinoin, trifluoperazine hydrochloride, trifluridine, trimetrexate, tumor necrosis factor, uracil mustard, vinblastine sulfate, vincristine sulfate, vindesine, vinorelbine, vinzolidine, Yoshi 864 (1-propanol-3,3'-iminodi-dimethanesulfonate [ester], hydrochloride), zorubicin, epothilone D, epothilone C, paclitaxel, docetaxel, ABJ879 (20-desmethyl-20-methylsulfanyl epothilone B), patupilone, MN-029 (Denibulin), BMS247550 (Ixabepilon), ecteinascidins, tetrahydroisoquinoline alkaloid, sirolimus, actinomycin, methotrexate, antiopeptin, vincristine, mitomycin, 2-chlorodeoxyadenosine, caspofungin, farnesylated dibenzodiazepinone, ECO-4601 (Dibenzodiazepoine), fluconazole, follistatin, leptin, midkine, angiogenin, angiopoietin-1, becaplermin, canstatin, angiostatin, endostatin, retinoids, tumistatin, vasculostatin, angioarrestin, vasostatin, bevacizumab, prinomastat, metformin, candesartan, diovan, diltiazem, atenolol, adalat, ranolazine, isosorbide dinitrate, rapamycin, everolimus, ABT 578 (Zotarolimus), AP23573 (Ridaforolimus, formerly known as deforolimus), CCI-779 (Temsirolimus), deuterated rapamycin, tacrolimus, cyclosporine, myriocin, aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nabumetone, acetaminophen, COX-2 inhibitors, nimesulide, NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide), flosulid, L-745337 (5-methanesulphonamido-6-(2,4-difluorothiophenyl)-1-indanone), celecoxib, rofecoxib, SC-57666 (1-fluoro-4-(2-(4-(methylsulfonyl)phenyl)cyclopent-1-enyl)benzene), DuP-697 (5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene), parecoxib sodium, JTE-522 (4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide), valdecoxib, SC-58125 (5-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-p- yrazole), etoricoxib, RS-57067 (6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3 (2H)-pyridazinone), L-48780 (5-Methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-1H-indol-3-yl]acetic acid), L-761066 ((R)-4-(1-(4-bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)-3-methylbutan- oic acid), APHS (o-(acetoxyphenyl)hept-2-ynyl sulphide), etodolac, meloxicam, S-2474 ((E)-(5)-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-ethyl-1,2-isothiazoli- dine-1,1-dioxide), glucocorticoids, hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethasone, fludrocortisone, desoxycorticosterone, fluticasone propionate, piroxicam, celeoxib, mefenamic acid, tramadol, meloxicam, methyl prednisone, pseudopterosin, hypercalcemia drugs, zoledronic acid, alendronate, antithrombosis drugs, heparin, clopidogrel, Fondaparinux Sodium, Nadroparin Calcium, and analogues, prodrugs, derivatives, precursors, fragments, salts, modifications and variations thereof. 13. A stent as in claim 1, wherein the passivation layer or the coating comprises a metal, a metal alloy, an oxide of a metal, an oxide of a metal alloy, a ceramic, a radiopaque agent, a polymer, or a combination thereof. 14. A stent as in claim 13, wherein the polymer is selected from the group consisting of polyurethane, polyethylenes imine, ethylene vinyl alcohol copolymer, silicone, thermoplastic elastomer, nylons, polyamide, polyimide, polytetrafluoroethylene (PTFE), parylene, parylast, poly(methyl methacrylate butyrate), poly-n-butyl methacrylate, poly butyl methacrylate copolymer with poly(ethylene vinyl acetate), poly(methyl methacrylate), poly 2-hydroxy ethyl methacrylate, poly ethylene glycol methacrylates, poly vinyl chloride, poly(dimethyl siloxane), poly ethylene vinyl acetate, poly carbonate, poly acrylamide gels, poly maleic anhydride, cellulose, cellulose acetate butyrate, proteins, fibrin, albumin, collagen, gelatin, oligosaccharides, polysaccharides, glycosoaminoglycans, chondroitin, chondroitin sulphates, phosholipids, phosphorylcholine, glycolipids; mixtures, copolymers, and combinations thereof. 15. A stent as in claim 1, wherein the passivation layer or the coating degrades at a slower rate than the body. 16. A stent as in claim 1, wherein the passivation layer or the coating slows down or delays degradation of the body. 17. A stent as in claim 1, wherein the passivation layer or the coating is non-porous or porous. 18. A stent as in claim 1, wherein the stent maintains greater than about 25% of strength after one month from implantation. 19. A stent as in claim 1, wherein the stent maintains greater than about 50% of strength after two months from implantation. 20. A stent as in claim 1, wherein the stent maintains greater than about 25% of strength after four months from implantation. 21. A stent as in claim 1, wherein the passivation layer thickness is less than 1 nm. 22. A stent as in claim 1, wherein the coating thickness ranges from 0.1 nm to 100 micrometer. 23. A stent as in claim 1, wherein the stent degrades in about four months to about two years in a physiological environment. 24. A stent as in claim 1, wherein the stent degrades in about six months to about one year in a physiological environment. 25. A stent as in claim 1, wherein the passivation layer or the coating comprises a degradation controlling element. 26. A stent as in claim 1, wherein the coating comprises a therapeutic agent. 27. A stent as in claim 26, wherein the therapeutic agent is in a polymer coating. 28. A stent as in claim 1, wherein the coating comprises a polymer. 29. A stent as in claim 28, wherein the polymer is fully degradable. 30. A stent as in claim 1, wherein the metal alloy is a zinc alloy. 31. A stent as in claim 1, wherein the corrosion resisting element is not corrodible. 32. A stent as in claim 1, wherein the stent further comprises a corrosion-inducing surface feature which causes at least a portion of the tubular body to degrade at a controlled degradation rate. 33. A stent as in claim 1, wherein at least one of said elements is not a metal. 34. A stent as in claim 1, wherein the degradation of the stent produces degradation byproducts which are physiologically benign. 35. A stent as in claim 1, wherein the stent further comprises at least one radiopaque marker. 36. A stent as in claim 1, wherein the stent further comprises degradable or non-degradable radiopaque markers or radiopaque coating. 37. A stent as in claim 1, wherein the degradation of the stent produces by products which are naturally occurring in a physiological environment. 38. A stent as in claim 1, wherein the stent has a variable degradation rate along its structure. 39. A stent as in claim 1, wherein the stent has at least two different degradation rates. 40. A stent as in claim 1, wherein the ends of the stent degrade faster than the area in between the ends. 41. A stent as in claim 1, wherein said coating degrades at a slower rate than the corrodible metal alloy. 42. A stent as in claim 1, wherein degradation of the stent or coating induces an inflammatory response in a body environment. 43. A stent as in claim 42, wherein said stent further comprises a therapeutic agent to treat inflammation. 44. A stent as in claim 1, wherein said body is formed from a metal hypotube. 45. A stent as in claim 1, wherein the stent has an average mass percentage loss of approximately 3% per day to 0.05% per day. 46. A stent as in claim 1, wherein the stent has an Icorr of 0.0001 amps/cm.sup.2 to 0.1 amps/cm.sup.2. 47. A stent as in claim 1 wherein the stent has an abluminal and luminal surfaces and the coating covers the abluminal surface of the stent. 48. A stent as in claim 1 wherein the stent has an abluminal and luminal surfaces and the coating covers the luminal surface of the stent.

Details for Patent 10,350,093

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-04-05
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2025-04-05
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2025-04-05